1Sindet-Pedersen C, Pallisgaard JL, Olesen JB, et al. Safety and efficacy of direct oral anticoagulants compared to warfarin for extended treatment of venous thromboembolism -a systematic review and meta-analysis[J]. Thromb Res, 2015, 136(4):732-738. 被引量：1
2Mandernach MW, Beyth RJ, Rajasekhar A. Apixaban for the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism: an evidence-based review[J]. Ther Clin Risk Manag, 2015(11): 1273-1282. 被引量：1
3Romualdi E, Ageno W. Investigational factor X a inhibitors for thrombosis and acute coronary syndromes[J]. Expert Opin Investig Drugs, 2011, 20(4):495-505. 被引量：1
4Heidbuchel H, Verhamme P, Alings M, et al. European Heart Rhythm Association. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non- valvular atrial fibrillation[J]. Europace, 2013, 15(5):625-651. 被引量：1
5Romualdi E, Donadini MP, Ageno W. Oral rivaroxaban after symptomatic venous thromboembolism: the continued treatment study (EINSTEIN-extension study)[J]. Expert Rev Cardiovasc Ther, 2011, 9(7):841-844. 被引量：1
6Weitz JI, Eikelboom JW, Samama MM, et al. New antithrombotic drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines[J]. Chest, 2012, 141(2 Suppl):e120S-e151S. 被引量：1
7Barrios V, Escobar C. Edoxaban in the prevention and treatment of thromboembolic complications from a clinical point of view[J]. Expert Rev Cardiovasc Ther, 2015, 13(7):811-824. 被引量：1
8Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty[J]. NEngl J Med,2008,358(26):2765-2775. 被引量：1
9Kakkar AK, Brenner B, Dalai OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial[J]. Lancet, 2008, 372(9632):31-39. 被引量：1
10Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty[J]. N Engl J Med, 2008, 358(26):2776-2786. 被引量：1
二级参考文献25
1Piovella F, Wang CJ, Lu H, et al. Deep-vein thrombosis ratesaftermajor orthopedic surgery in Asia. An ep idemiological studybased on postoperative screening with centrally adjudicatedbilateral venography [ J]. J Thromb Haemost, 2005,3 : 2664 -2670. 被引量：1
2Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venousthromboembolism. American College of Chest Physicians evidence-based clinical practice guidelines ( 8th edn) [ J]. Chest, 2008 ,133: 381S-453S. 被引量：1
3Donald JP, Michael JO, Stephanie K, et al. Discovery of 1-(4-Methoxyphenyl) -7-oxo-6-(4-( 2-oxopiperidin-l -yl) phenyl) A,5,6,7-tetrahydro-l H-pyrazolo [ 3, 4-c ] pyridine-3 -carboxamide(apixaban, BMS-562247 ),a highly potent, selective,efficacious, and orally bioavmlable inhibitor of blood coagulationfactor Xa [ J ]. J Med Chem, 2007,50: 5339 -5356. 被引量：1
4Bauer KA.Pros and cons of new oral anticoagulants[J].Hematology Am Soc Hematol Educ Program,2013,2013:464-470. 被引量：1
5Connolly SJ,Ezekowitz MD,Yusuf S,et al.Dabigatran versus warfarin in patients with atrial fibrillation[J].N Engl J Med,2009,361(12):1139-1151. 被引量：1
6Patel MR,Mahaffey KW,Garg J,et al.Rivaroxaban versus warfarin in nonvalvular atrial fibrillation[J].N Engl J Med,2011,365(10):883-891. 被引量：1
7Granger CB,Alexander JH,Mc Murray JJ,et al.Apixaban versus warfarin in patients with atrial fibrillation[J].N Engl J Med,2011,365(11):981-992. 被引量：1
8Patel MR,Hellkamp AS,Lokhnygina Y,et al.Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation:analysis from the ROCKET AF trial(Rivaroxaban Once-Daily,Oral,Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)[J].J Am Coll Cardiol,2013,61(6):651-658. 被引量：1
9Eriksson BI,Borris LC,Friedman RJ,et al.Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty[J].N Engl J Med,2008,358(26):2765-2775. 被引量：1
10Kakkar AK,Brenner B,Dahl OE,et al.Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty:a doubleblind,randomised controlled trial[J].Lancet,2008,372(9632):31-39. 被引量：1
